EE146 Cost-Effectiveness of Axicabtagene Ciloleucel Versus Other CAR T-Cell Therapies in the Treatment of Diffuse Large B-Cell Lymphoma in France

Abstract

Authors

N Brighton A Zang JG Castaigne

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×